INTREPID Alliance Launches Antiviral Toolbox to Support Global Research Community
Open-access resource includes Registry of Antiviral Compound Libraries to help catalyze drug…
Baylor Genetics to Highlight Genetic Testing Use Cases and Advancements in Rare Disease at The National Society of Genetic Counselors 44th Annual Conference
HOUSTON, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Baylor Genetics, a clinical diagnostic…
LUMOSA THERAPEUTICS ANNOUNCES POSITIVE RESULTS FROM LT3001(INTRAVENOUS ODATROLTIDE) PHASE 2B CLINICAL TRIAL IN ACUTE ISCHEMIC STROKE
Results presented at the 17th World Stroke Congress (WSC 2025) LT3001(Odatroltide)-202 phase…
FibroBiologics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
October 31, 2025 16:30 ET | Source: FibroBiologics, Inc. Advancing preparations to…
ArkBio Initiates Phase II Clinical Trial of AK0610, a Preventive Monoclonal Antibody for Respiratory Syncytial Virus Infection
SHANGHAI, Oct. 30, 2025 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio")…
Avacta presents first preclinical data from dual payload pre|CISION medicines at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets
First-in-class dual payload peptide drug conjugate delivers two complementary therapies from a…
ACM Biolabs Reports Favorable Safety Signals and Early Pharmacodynamics from Intramuscular Administration of ACM-CpG in Patients with Advanced Solid Tumors
SINGAPORE, Oct. 22, 2025 /PRNewswire/ -- ACM Biolabs, a clinical-stage biotechnology company developing next-generation…
Kura Oncology Receives $30 Million Development Milestone Payment in Ziftomenib AML Program with Kyowa Kirin
October 24, 2025 07:02 ET | Source: Kura Oncology, Inc. - Milestone…
Denifanstat Achieved All Endpoints in the Treatment of Moderate to Severe Acne in Phase 3 Clinical Trial in Acne in China: A Presentation at the 2025 Fall Clinical Dermatology Conference
October 24, 2025 07:00 ET | Source: Sagimet Biosciences Inc. Denifanstat met…
GT Biopharma Provides Enrollment Update on GTB-3650 Phase 1 Trial in Patients with Relapsed or Refractory (r/r) CD33 Expressing Hematologic Malignancies
The formal safety review of Cohort 3 (5ug/kg/day) has been successfully completed…